An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.
Tag: Clinical Trials
The Push for a Better Dengue Vaccine Grows More Urgent
A public research institute in Brazil has proved a new shot protects against the disease, but can’t make it fast enough to stop the huge outbreak sweeping Latin America.
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy
New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.
Powerful Psychedelic Drug Gains New Notice as an Opioid Addiction Therapy
New research is stirring interest in ibogaine, which appears to help ease the agony of detox and prevent relapse. Used in other countries, it remains illegal in the U.S.
New Hope — and an Old Hurdle — for a Terrible Disease With Terrible Treatments
Researchers in developing countries are trying to find treatments for conditions that affect the poorest people. But the system is stacked against their therapies.
Could Longevity Drugs for Dogs Extend Your Pet’s Life?
Longevity drugs for our canine companions are moving closer to reality. They also raise questions about what it might mean to succeed.
Gonorrhea Is Becoming Drug Resistant. Scientists Just Found a Solution.
A new antibiotic, zoliflodacin, is as effective as the current standard of care. Its creation may hasten the arrival of other needed antibiotics.
Ending TB Is Within Reach — So Why Are Millions Still Dying?
Tuberculosis has passed Covid as the top infectious disease killer, despite new medicines and better diagnostic tools.
New Marburg Outbreaks in Africa Raise Alarm About the Deadly Virus’s Spread
The spread of the Ebola-like virus has claimed lives but could be a crucial chance to test a vaccine — if supplies and researchers are mobilized in time.
Why the Odds Are Stacked Against a Promising New Covid Drug
A new drug quashes all coronavirus variants. But regulatory hurdles and a lack of funding make it unlikely to reach the U.S. market anytime soon.